Iirimaa - inglise - HPRA (Health Products Regulatory Authority)

accord healthcare ireland ltd. - esomeprazole magnesium dihydrate - gastro-resistant tablet - 20 milligram(s) - proton pump inhibitors; esomeprazole

Suurbritannia - inglise - MHRA (Medicines & Healthcare Products Regulatory Agency)

viatris uk healthcare ltd - esomeprazole magnesium dihydrate - gastro-resistant capsule - 20mg

Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - esomeprazole magnesium dihydrate, quantity: 43.37 mg - capsule, enteric - excipient ingredients: triethyl citrate; dimeticone 350; diacetylated monoglycerides; sucrose; gelatin; maize starch; mannitol; iron oxide yellow; methacrylic acid - ethyl acrylate copolymer (1:1); titanium dioxide; purified talc; stearoyl macrogolglycerides; polysorbate 80; hypromellose; purified water - gastro-oesophageal reflux disease (gord),? treatment of erosive reflux oesophagitis,? long-term management of patients with healed oesophagitis to prevent relapse,? symptomatic treatment of gastro-oesophageal reflux disease (gord),patients requiring nsaid therapy,? short-term treatment of upper gastrointestinal symptoms associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy.,? healing of gastric ulcers associated with non-steroidal anti-inflammatory,drug nsaid (non-selective and cox-2 selective) therapy,? prevention of gastric and duodenal ulcers associated with non-steroidal anti inflammatory drug nsaid (non-selective and cox-2 selective) therapy in patients at risk.,prevention of rebleeding of gastric or duodenal ulcers following treatment with iv esomeprazole solution by intravenous infusion.,pathological hypersecretory conditions including zollinger-ellison syndrome and idiopathic hypersecretion,in combination with appropriate antibiotics for:,? healing of duodenal ulcer associated with helicobacter pylori,? eradication of helicobacter pylori in patients with active or healed peptic ulcer

Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - esomeprazole magnesium dihydrate, quantity: 21.69 mg - capsule, enteric - excipient ingredients: titanium dioxide; purified water; dimeticone 350; mannitol; gelatin; stearoyl macrogolglycerides; maize starch; iron oxide yellow; diacetylated monoglycerides; triethyl citrate; sucrose; hypromellose; purified talc; polysorbate 80; methacrylic acid - ethyl acrylate copolymer (1:1) - gastro-oesophageal reflux disease (gord),? treatment of erosive reflux oesophagitis,? long-term management of patients with healed oesophagitis to prevent relapse,? symptomatic treatment of gastro-oesophageal reflux disease (gord),patients requiring nsaid therapy,? short-term treatment of upper gastrointestinal symptoms associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy.,? healing of gastric ulcers associated with non-steroidal anti-inflammatory,drug nsaid (non-selective and cox-2 selective) therapy,? prevention of gastric and duodenal ulcers associated with non-steroidal anti inflammatory drug nsaid (non-selective and cox-2 selective) therapy in patients at risk.,prevention of rebleeding of gastric or duodenal ulcers following treatment with iv esomeprazole solution by intravenous infusion.,pathological hypersecretory conditions including zollinger-ellison syndrome and idiopathic hypersecretion,in combination with appropriate antibiotics for:,? healing of duodenal ulcer associated with helicobacter pylori,? eradication of helicobacter pylori in patients with active or healed peptic ulcer

Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - esomeprazole magnesium dihydrate, quantity: 43.37 mg - capsule, enteric - excipient ingredients: gelatin; purified talc; iron oxide yellow; methacrylic acid - ethyl acrylate copolymer (1:1); mannitol; diacetylated monoglycerides; sucrose; triethyl citrate; dimeticone 350; maize starch; stearoyl macrogolglycerides; purified water; polysorbate 80; titanium dioxide; hypromellose - gastro-oesophageal reflux disease (gord),? treatment of erosive reflux oesophagitis,? long-term management of patients with healed oesophagitis to prevent relapse,? symptomatic treatment of gastro-oesophageal reflux disease (gord),patients requiring nsaid therapy,? short-term treatment of upper gastrointestinal symptoms associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy.,? healing of gastric ulcers associated with non-steroidal anti-inflammatory,drug nsaid (non-selective and cox-2 selective) therapy,? prevention of gastric and duodenal ulcers associated with non-steroidal anti inflammatory drug nsaid (non-selective and cox-2 selective) therapy in patients at risk.,prevention of rebleeding of gastric or duodenal ulcers following treatment with iv esomeprazole solution by intravenous infusion.,pathological hypersecretory conditions including zollinger-ellison syndrome and idiopathic hypersecretion,in combination with appropriate antibiotics for:,? healing of duodenal ulcer associated with helicobacter pylori,? eradication of helicobacter pylori in patients with active or healed peptic ulcer

Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - esomeprazole magnesium dihydrate, quantity: 21.69 mg - capsule, enteric - excipient ingredients: gelatin; mannitol; diacetylated monoglycerides; sucrose; dimeticone 350; titanium dioxide; triethyl citrate; purified talc; hypromellose; polysorbate 80; stearoyl macrogolglycerides; maize starch; methacrylic acid - ethyl acrylate copolymer (1:1); iron oxide yellow; purified water - gastro-oesophageal reflux disease (gord),? treatment of erosive reflux oesophagitis,? long-term management of patients with healed oesophagitis to prevent relapse,? symptomatic treatment of gastro-oesophageal reflux disease (gord),patients requiring nsaid therapy,? short-term treatment of upper gastrointestinal symptoms associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy.,? healing of gastric ulcers associated with non-steroidal anti-inflammatory,drug nsaid (non-selective and cox-2 selective) therapy,? prevention of gastric and duodenal ulcers associated with non-steroidal anti inflammatory drug nsaid (non-selective and cox-2 selective) therapy in patients at risk.,prevention of rebleeding of gastric or duodenal ulcers following treatment with iv esomeprazole solution by intravenous infusion.,pathological hypersecretory conditions including zollinger-ellison syndrome and idiopathic hypersecretion,in combination with appropriate antibiotics for:,? healing of duodenal ulcer associated with helicobacter pylori,? eradication of helicobacter pylori in patients with active or healed peptic ulcer

Belgia - inglise - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

eg sa-nv - esomeprazole magnesium dihydrate 21,69 mg - eq. esomeprazole 20 mg - gastro-resistant capsule, hard - 20 mg - esomeprazole magnesium dihydrate 21.69 mg - esomeprazole

Belgia - inglise - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

eg sa-nv - esomeprazole magnesium dihydrate 43,37 mg - eq. esomeprazole 40 mg - gastro-resistant capsule, hard - 40 mg - esomeprazole magnesium dihydrate 43.37 mg - esomeprazole

Belgia - inglise - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

teva pharma belgium sa-nv - esomeprazole magnesium dihydrate 43,376 mg - eq. esomeprazole 40 mg - gastro-resistant capsule, hard - 40 mg - esomeprazole magnesium dihydrate 43.376 mg - esomeprazole

Belgia - inglise - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

teva pharma belgium sa-nv - esomeprazole magnesium dihydrate 21,688 mg - eq. esomeprazole 20 mg - gastro-resistant capsule, hard - 20 mg - esomeprazole magnesium dihydrate 21.688 mg - esomeprazole